ABIVAX Société Anonyme (ABVX) to Release Quarterly Earnings on Monday

ABIVAX Société Anonyme (NASDAQ:ABVX) is expected to be issuing its quarterly earnings data before the market opens on Monday, June 2nd. Analysts expect the company to announce earnings of ($1.59) per share and revenue of $3.11 million for the quarter.

ABIVAX Société Anonyme Price Performance

NASDAQ ABVX opened at $5.67 on Monday. ABIVAX Société Anonyme has a 12 month low of $4.77 and a 12 month high of $14.71. The stock has a 50 day moving average of $6.37 and a 200-day moving average of $7.07.

Wall Street Analysts Forecast Growth

ABVX has been the subject of several recent analyst reports. JMP Securities reissued a “market outperform” rating and issued a $33.00 price objective on shares of ABIVAX Société Anonyme in a report on Wednesday, April 30th. Morgan Stanley restated an “equal weight” rating and issued a $12.00 price target on shares of ABIVAX Société Anonyme in a research note on Thursday, March 20th.

Institutional Investors Weigh In On ABIVAX Société Anonyme

Large investors have recently added to or reduced their stakes in the business. Bank of America Corp DE raised its stake in ABIVAX Société Anonyme by 56.1% in the 4th quarter. Bank of America Corp DE now owns 5,536 shares of the company’s stock valued at $41,000 after acquiring an additional 1,990 shares during the period. Cubist Systematic Strategies LLC increased its position in ABIVAX Société Anonyme by 34.3% during the 1st quarter. Cubist Systematic Strategies LLC now owns 10,152 shares of the company’s stock worth $63,000 after buying an additional 2,595 shares during the period. Woodline Partners LP increased its position in ABIVAX Société Anonyme by 319.5% during the 1st quarter. Woodline Partners LP now owns 201,924 shares of the company’s stock worth $1,262,000 after buying an additional 153,788 shares during the period. Finally, Millennium Management LLC increased its position in ABIVAX Société Anonyme by 6.0% during the 1st quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock worth $6,171,000 after buying an additional 56,235 shares during the period. Institutional investors own 47.91% of the company’s stock.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.